Submit Deal

FAIRMOUNT FUNDS MANAGEMENT

Summary

Fairmount is a registered investment adviser with $1bn+ AUM dedicated to investing in promising new biotechnology companies with a focus on differentiated therapeutics, robust research organizations, and experienced management teams.

Deals Overview

Total Deals7

Valued Deals6

Total Value£ 1.05 B

Avg. Deal Size£ 176 M

Market Context

Senior Management

Peter Harwin
Partner

Sort

28 Oct 2020|United States|Biotechnology

Target: MIRAGEN THERAPEUTICS

Bidder: VENROCK

16 Service Providers

5 Target | 11 Bidder

19 Dealmakers

5 Target | 14 Bidder

£ 70 M

Value

07 Nov 2022|United States|Biotechnology

Target: ZENAS BIOPHARMA

Bidder: AGENT CAPITAL

13 Service Providers

1 Target | 12 Bidder

14 Dealmakers

2 Target | 12 Bidder

£ 103 M

Value

07 Dec 2022|United States|Biotechnology

Target: APOGEE THERAPEUTICS

Bidder: PERCEPTIVE ADVISORS LLC

3 Service Providers

2 Target | 1 Bidder

3 Dealmakers

2 Target | 1 Bidder

£ 122 M

Value

14 Feb 2024|United States|Biotechnology

Target: COGENT BIOSCIENCES

Bidder: REDMILE GROUP

5 Service Providers

5 Target

3 Dealmakers

3 Target

£ 284 M

Value

21 Mar 2024|United States|Pharmaceuticals

Target: MIRADOR THERAPEUTICS

Bidder: ORBIMED ADVISORS LLC

4 Service Providers

3 Target | 1 Bidder

7 Dealmakers

6 Target | 1 Bidder

£ 314 M

Value

07 May 2024|United States|Biotechnology

Target: ZENAS BIOPHARMA

Bidder: FEDERATED HERMES

4 Service Providers

3 Target | 1 Bidder

2 Dealmakers

1 Target | 1 Bidder

£ 160 M

Value

31 Oct 2024|United States|Biotechnology

Target: AEROVATE THERAPEUTICS

Bidder: VENROCK HEALTHCARE CAPITAL PARTNERS

11 Service Providers

4 Target | 7 Bidder

5 Dealmakers

1 Target | 4 Bidder

n/a

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy